
Major Scope
- Lung Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Breast Cancer
- Prostate Cancer
- Liver Cancer
- Leukemia
- Bladder Cancer
- Kidney Cancer
- Endometrial Cancer
- Oncology Case Reports
- Radiation Therapy
Abstract
Citation: Clin Oncol. 2021;6(1):1874.DOI: 10.25107/2474-1663-v6-id1874
NLRP3 Inflammasome Enhances Tumor Growth
Bernhard Ryffel
Laboratory of Experimental and Molecular Immunology and Neurogenetics (INEM), UMR 7355 CNRS-University of Orleans, Orleans, France
*Correspondance to: Bernhard Ryffel
PDF Full Text Mini Review | Open Access
Abstract:
Tumor cell derived danger signals known as DAMPs activate the NLRP3 inflammasome leading to IL-1β/IL-18 production conferring a pro-inflammatory environment. The inflammatory tumor environment enhances the tumor progression and metastasis. The NLRP3 inflammasome or IL-1/IL-18 represents promising therapeutic targets in cancer therapy, which is discussed in this
review. Alternative targets such TLRs and cGAS/STING dependent immune regulators need to be considered. The metabolome and microbiome of the host are additional factors contributing to a successful chemo- and immunotherapy.
Keywords:
Cite the Article:
Ryffel B. NLRP3 Inflammasome Enhances Tumor Growth. Clin Oncol. 2021;6:1874..
Journal Basic Info
- Impact Factor: 3.231**
- H-Index: 11
- ISSN: 2474-1663
- DOI: 10.25107/2474-1663
- PubMed NLM ID: 101705590